Fred Aslan
Chief Executive Officer, Director · Artiva Biotherapeutics, Inc.
- 2025
- Oct 7, 2026
- 11
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Fred Aslan files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- RA CAPITAL MANAGEMENT, L.P. - $117.62M in ARTV purchases and sales in the last 12 months
- GC Corp. - $16.50M in ARTV purchases and sales in the last 12 months
- Christopher Horan - $249K in ARTV purchases and sales in the last 12 months
- Jennifer Bush - $230K in ARTV purchases and sales in the last 12 months
- Subhashis Banerjee - $187K in ARTV purchases and sales in the last 12 months
- Heather Raymon - $28K in ARTV purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Fred Aslan?
Fred Aslan is a corporate insider, tracked as Chief Executive Officer, Director of Artiva Biotherapeutics, Inc. (ARTV). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Fred Aslan submitted recently?
5 primary Form 4 filings in the last 90 days, covering 1 company.
Has Fred Aslan been buying or selling stock?
Recorded transactions: 0 open-market purchases and 8 open-market sales ($2.03M) across all tracked filings.
